Astellas has re-invested in Coda Biotherapeutics, which is working on therapies for conditions such as focal epilepsy and chronic neuropathic pain.
Coda Biotherapeutics, a US-based gene therapy developer targeting intractable neurological diseases, increased its series A round to $34m on Tuesday with an extension backed by Astellas Venture Management, the investment arm of drug developer Astellas.
The extension was led by venture capital firm Versant Ventures and also featured life sciences-focused VC firm MPM Capital, after the same duo co-led an initial $19m tranche in September 2018 involving Astellas and its peer Novartis.
Coda Biotherapeutics is developing engineered neurotransmitted receptors…
